柔肝方对肝纤维化小鼠肝脏内IL⁃22分泌和IL⁃22R1表达作用的研究

厉姣龙; 周振华

doi:10.16306/j.1008-861x.2022.05.012

您当前的位置：

首页 >

文章列表页 >

柔肝方对肝纤维化小鼠肝脏内IL⁃22分泌和IL⁃22R1表达作用的研究

实验研究 | 更新时间：2022-11-01

- 柔肝方对肝纤维化小鼠肝脏内IL⁃22分泌和IL⁃22R1表达作用的研究
- Study on effects of Rougan Formula on IL⁃22 secretion and IL⁃22R1 expression in liver of mice with liver fibrosis
- 上海中医药大学学报 2022年36卷第5期页码：69-76
- 作者机构：
  
  1.上海中医药大学，上海中医药大学附属曙光医院（上海　201203）
- 作者简介：
  
  厉姣龙，女，在读硕士生，主要从事中医药防治慢性肝病的临床和基础研究
  周振华，副研究员，硕士生导师；E-mail：jinghua1220@163.com
- 基金信息：
  
  国家自然科学基金资助项目(81774268);上海市科技创新行动计划临床医学领域项目(19401972500);上海市科技创新行动计划生物医药科技支撑专项项目(21S21900400)
- DOI：10.16306/j.1008-861x.2022.05.012
  中图分类号：
扫描看全文
厉姣龙,周振华.柔肝方对肝纤维化小鼠肝脏内IL⁃22分泌和IL⁃22R1表达作用的研究[J].上海中医药大学学报,2022,36(05):69-76.

LI Jiaolong,ZHOU Zhenhua.Study on effects of Rougan Formula on IL⁃22 secretion and IL⁃22R1 expression in liver of mice with liver fibrosis[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2022,36(05):69-76.
厉姣龙,周振华.柔肝方对肝纤维化小鼠肝脏内IL⁃22分泌和IL⁃22R1表达作用的研究[J].上海中医药大学学报,2022,36(05):69-76. DOI： 10.16306/j.1008-861x.2022.05.012.

LI Jiaolong,ZHOU Zhenhua.Study on effects of Rougan Formula on IL⁃22 secretion and IL⁃22R1 expression in liver of mice with liver fibrosis[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2022,36(05):69-76. DOI： 10.16306/j.1008-861x.2022.05.012.

摘要

目的,2,监测柔肝方对刀豆蛋白A（ConA）联合3,5-二乙氧基羰基-1,4-二氢-2,4,6-三甲基吡啶（DDC）诱导的肝纤维化小鼠肝脏内白介素-22（IL-22）分泌及白介素-22受体1（IL-22R1）表达的影响，探讨柔肝方抗肝纤维化的作用机制。,方法,2,60只小鼠随机分为对照组、模型组和柔肝方组，每组20只。模型组和柔肝方组小鼠尾静脉注射ConA，每周1次，并予DDC饮食；对照组小鼠尾静脉注射等体积0.9% NaCl溶液，正常饮食。柔肝方组小鼠按8.5 g/kg灌胃给予柔肝方颗粒，每天1次；对照组和模型组小鼠灌胃给予等体积0.9% NaCl溶液。药物连续干预10周。10周后处死小鼠，监测各组小鼠肝功能、肝脏中IL-22分泌及IL-22R1表达。,结果,2,①与对照组比较，模型组和柔肝方组小鼠肝脏中,IL⁃22,、,IL⁃22R1,、,IL⁃10R2,和,STAT3 ,mRNA表达明显升高（,P,<,0.01，,P,<,0.001）；与模型组比较，柔肝方组小鼠肝脏中,IL⁃22,和,IL⁃10R2, mRNA表达明显升高（,P,<,0.001）。②与对照组比较，模型组肝星状细胞（HSCs）表面的,IL⁃22R1 ,mRNA表达明显升高（,P,<,0.05）、HSCs内的,STAT3 ,mRNA表达明显升高（,P,<,0.05），柔肝方组HSCs表面的,IL⁃22R1,和,IL⁃10R2 ,mRNA表达明显升高（,P,<,0.05，,P,<,0.001），柔肝方组HSCs内的,STAT3 ,mRNA表达升高（,P,<,0.001）；与模型组比较，柔肝方组HSCs表面的,IL⁃22R1 ,mRNA和HSCs内的,STAT3 ,mRNA表达明显升高（,P,<,0.01，,P,<,0.001）。③与对照组比较，模型组和柔肝方组Th22细胞数量明显增加（,P,<,0.001）；与模型组比较，柔肝方组Th22细胞数量明显增加（,P,<,0.01）。,结论,2,柔肝方可增加肝脏内IL-22分泌及HSCs表面IL-22R1的表达，从而发挥抗肝纤维化的作用。

Abstract

Objective： To study the effects of Rougan Formula on interleukin-22 （IL-22） secretion and IL-22 receptor 1 （IL-22R1） expression in the liver of concanavalin A （ConA） combined with 3,5-diethoxy carbonyl-1,4-dihydro-2,4,6-trimethylpyridine （DDC） induced liver fibrosis mice， and to explore the mechanism of Rougan Formula against liver fibrosis.,Methods,2,Sixty mice were randomly divided into control group， model group and Rougan Formula group， with 20 mice in each group. The mice in the model group and Rougan Formula group were injected with ConA through the tail vein once a week and fed with DDC diet. The mice in the control group were injected with equal volume of 0.9% NaCl solution through the tail vein and fed with normal diet. The mice in Rougan Formula group were given Rougan Formula granules by gavage （8.5 g/kg） once a day. The mice in control and model group were given equal volume of 0.9% NaCl solution by gavage. The Drug intervention lasted for 10 weeks. The mice were killed after 10 weeks， liver function， secretion of IL-22 and expression of IL-22R1 in liver were observed.,Results,2,①Compared with the control group， the expression of, IL,-,22，,IL,-,22R1,， ,IL,-,10R2, and ,STAT3, mRNA in the liver of mice in the model group and Rougan Formula group significantly increased （,P,<,0.01，,P,<,0.001）. Compared with the model group， the expression of ,IL,-,22, and ,IL,-,10R2, mRNA in the liver of mice in the Rougan Formula group significantly increased （,P,<,0.001）. ②Compared with the control group， the expression of ,IL,-,22R1, mRNA on the surface of hepatic stellate cells （HSCs） in the model group significantly increased （,P,<,0.05）， the expression of ,STAT3, mRNA in HSCs significantly increased （,P,<,0.05）， the expression of, IL,-,22R1, and ,IL,-,10R2, mRNA on the surface of HSCs in the Rougan Formula group significantly increased （,P,<,0.05，,P,<,0.001）， and the expression of ,STAT3, mRNA in HSCs in the Rougan Formula group significantly increased （,P,<,0.001）. Compared with the model group， the expression of ,IL,-,22R1, mRNA on the surface of HSCs and ,STAT3, mRNA in HSCs in the Rougan Formula group significantly increased （,P,<,0.01，,P,<,0.001）. ③Compared with the control group， the number of Th22 cells in the model group and Rougan Formula group significantly increased （,P,<,0.001）. Compared with the model group， the number of Th22 cells in the Rougan Formula group significantly increased （,P,<,0.01）.,Conclusion,2,Rougan Formula can increase the secretion of IL-22 in the liver and the expression of IL-22R1 on the surface of HSCs， so as to play the role of anti-hepatic fibrosis.

关键词

柔肝方肝纤维化IL-22IL-22R1

Keywords

Rougan Formulahepatic fibrosisIL-22IL-22R1

references

PAROLA M，PINZANI M. Liver fibrosis： Pathophysiology，pathogenetic targets and clinical issues［J］. Mol Aspects Med，2019， 65： 37-55.

TSUCHIDA T，FRIEDMAN S L. Mechanisms of hepatic stellate cell activation［J］. Nat Rev Gastroenterol Hepatol， 2017， 14（7）： 397-411.

CHEN Y，FAN Y，GUO D Y，et al. Study on the relationship between hepatic fibrosis and epithelial-mesenchymal transition in intrahepatic cells［J］. Biomed Pharmacother， 2020， 129： 110413.

KISSELEVA T，BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression［J］. Nat Rev Gastroenterol Hepatol， 2021， 18（3）： 151-166.

KONG D， ZHANG Z， CHEN L， et al. Curcumin blunts epithelial-mesenchymal transition of hepatocytes to alleviate hepatic fibrosis through regulating oxidative stress and autophagy［J］. Redox Biol，2020， 36： 101600.

RODERFELD M. Matrix metalloproteinase functions in hepatic injury and fibrosis［J］. Matrix Biol， 2018， 68-69： 452-462.

ZONG Z， LIU J， WANG N， et al. Nicotinamide mononucleotide inhibits hepatic stellate cell activation to prevent liver fibrosis via promoting PGE2 degradation［J］. Free Radic Biol Med， 2021， 162： 571-581.

YANG W，YU T，HUANG X，et al. Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity［J］. Nat Commun，2020，11（1）：4457.

孟昱希，霍丽娟. IL-22在肝纤维化发生发展中的作用［J］. 临床肝胆病杂志，2021， 37（12）： 2924-2927.

ZENEWICZ L A， YANCOPOULOS G D， VALENZUELA D M， et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation［J］. Immunity， 2007， 27（4）： 647-659.

SABIHI M，BOTTCHER M，PELCZAR P，et al. Microbiota-Dependent Effects of IL-22［J］. Cells， 2020， 9（10）： 2205.

MIZOGUCHI A， YANO A， HIMURO H， et al. Clinical importance of IL-22 cascade in IBD［J］. J Gastroenterol， 2018， 53（4）： 465-474.

SONNENBERG G F， FOUSER L A， ARTIS D. Border patrol： regulation of immunity，inflammation and tissue homeostasis at barrier surfaces by IL-22［J］. Nat Immunol， 2011， 12（5）： 383-390.

EYERICH K，DIMARTINO V，CAVANI A. IL-17 and IL-22 in immunity： Driving protection and pathology［J］. Eur J Immunol， 2017， 47（4）： 607-614.

KHAWAR M B， AZAM F， SHEIKH N， et al. How Does Interleukin-22 Mediate Liver Regeneration and Prevent Injury and Fibrosis？［J］. J Immunol Res， 2016， 2016： 2148129.

王灵台，陈建杰，张斌，等. 柔肝冲剂抗肝纤维化的临床研究［J］. 上海中医药杂志，2001， 35（10）： 7-9.

黄凌鹰，张鑫，李曼，等. 柔肝方上调肝组织Dectin-1及下调TLR4治疗CCl4造模小鼠肝纤维化的作用机制研究［J］. 上海中医药杂志，2020， 54（S1）： 167-170， 176.

李茜，吴惠春，谭家鑫，等. 柔肝方通过抑制纤维化蛋白抗肝纤维化的机制研究［J］. 中国免疫学杂志，2022， 38（3）： 263-269.

胡翘廷，蒋煜川，涂梦仙，等. 改良法分离肝纤维化不同阶段小鼠肝星状细胞［J］. 中华实验外科杂志，2019， 36（2）： 255-257.

徐莹，张定棋，慕永平，等. 提高小鼠原代肝星状细胞获得率及纯度的分离方法［J］. 中国组织工程研究，2018， 22（21）： 3376-3380.

解清，孙璇，闫赖赖，等. Percoll密度梯度离心法在血液组分分离及元素测定中的应用［J］. 中国卫生检验杂志，2015， 25（7）： 954-958.

RIBERA J，VILCHES C，SANZ V，et al. Treatment of Hepatic Fibrosis in Mice Based on Targeted Plasmonic Hyperthermia［J］. ACS Nano， 2021， 15（4）： 7547-7562.

赵钢. 从“灵甲胶囊”的研制思路及过程，论王灵台教授对肝纤维化病机学说及治疗的发展［J］. 实用肝脏病杂志，2010， 13（1）： 58-60.

GAO B，XIANG X. Interleukin-22 from bench to bedside： a promising drug for epithelial repair［J］. Cell Mol Immunol， 2019， 16（7）： 666-667.

HWANG S， HE Y， XIANG X， et al. Interleukin-22 Ameliorates Neutrophil-Driven Neutrophil-Driven Nonalcoholic Steatohepatitis Through Multiple Targets［J］. Hepatology， 2020， 72（2）： 412-429.

SCHWARZKOPF K，RUSCHENBAUM S， BARAT S，et al. IL-22 and IL-22-Binding Protein Are Associated With Development of and Mortality From Acute-on-Chronic Liver Failure［J］. Hepatol Commun， 2019， 3（3）： 392-405.

浏览量

155

下载量

CSCD

CNKI被引量

文章被引用时，请邮件提醒。

提交

工具集

关联资源

四氯化碳及二甲基亚硝胺诱导肝纤维化小鼠肝脏淋巴细胞亚群变化特点及扶正化瘀方调节作用

补肾柔肝方抑制血管新生的抗小鼠肝纤维化作用机制

健脾柔肝方联合恩替卡韦治疗慢性乙型病毒性肝炎肝纤维化的临床研究